Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ:PCSA
Total Valuation
Processa Pharmaceuticals has a market cap or net worth of $7.37M. The enterprise value is $739.22K.
Market Cap$7.37M
Enterprise Value$739.22K
Share Statistics
Processa Pharmaceuticals has 2,660,039 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,660,039
Owned by Insiders12.03%
Owned by Institutions0.54%
Financial Efficiency
Processa Pharmaceuticals’s return on equity (ROE) is -2.43 and return on invested capital (ROIC) is -250.81%.
Return on Equity (ROE)-2.43
Return on Assets (ROA)-1.74
Return on Invested Capital (ROIC)-250.81%
Return on Capital Employed (ROCE)-2.51
Revenue Per Employee0.00
Profits Per Employee-1.36M
Employee Count10
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Processa Pharmaceuticals is ―. Processa Pharmaceuticals’s PEG ratio is 0.00311.
PE Ratio―
PS Ratio0.00
PB Ratio0.68
Price to Fair Value0.68
Price to FCF-0.33
Price to Operating Cash Flow-0.50
PEG Ratio0.00311
Income Statement
In the last 12 months, Processa Pharmaceuticals had revenue of 0.00 and earned -13.56M in profits. Earnings per share was -10.36.
Revenue0.00
Gross Profit-1.20K
Operating Income-13.99M
Pretax Income-13.56M
Net Income-13.56M
EBITDA-13.99M
Earnings Per Share (EPS)-10.36
Cash Flow
In the last 12 months, operating cash flow was -14.12M and capital expenditures 0.00, giving a free cash flow of -14.12M billion.
Operating Cash Flow-14.12M
Free Cash Flow-14.12M
Free Cash Flow per Share-5.31
Dividends & Yields
Processa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change-62.31%
50-Day Moving Average2.57
200-Day Moving Average5.07
Relative Strength Index (RSI)54.28
Average Volume (3m)44.23K
Important Dates
Processa Pharmaceuticals upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Processa Pharmaceuticals as a current ratio of 2.54, with Debt / Equity ratio of 0.00%
Current Ratio2.54
Quick Ratio2.54
Debt to Market Cap0.00
Net Debt to EBITDA0.40
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Processa Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Processa Pharmaceuticals EV to EBITDA ratio is 0.13, with an EV/FCF ratio of 0.16.
EV to Sales0.00
EV to EBITDA0.13
EV to Free Cash Flow0.16
EV to Operating Cash Flow0.16
Balance Sheet
Processa Pharmaceuticals has $5.54M in cash and marketable securities with $0.00 in debt, giving a net cash position of $5.54M billion.
Cash & Marketable Securities$5.54M
Total Debt$0.00
Net Cash$5.54M
Net Cash Per Share$2.08
Tangible Book Value Per Share$3.39
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Processa Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast72.88%